132 related articles for article (PubMed ID: 29843102)
1. Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
Hsu PH; Chiu DC; Wu KL; Lee PS; Jan JT; Cheng YE; Tsai KC; Cheng TJ; Fang JM
Eur J Med Chem; 2018 Jun; 154():314-323. PubMed ID: 29843102
[TBL] [Abstract][Full Text] [Related]
2. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
Liu KC; Lee PS; Wang SY; Cheng YS; Fang JM; Wong CH
Bioorg Med Chem; 2011 Aug; 19(16):4796-802. PubMed ID: 21778065
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities.
Lin CH; Chang TC; Das A; Fang MY; Hung HC; Hsu KC; Yang JM; von Itzstein M; Mong KK; Hsu TA; Lin CC
Org Biomol Chem; 2013 Jun; 11(24):3943-8. PubMed ID: 23695381
[TBL] [Abstract][Full Text] [Related]
4. Tamiphosphor monoesters as effective anti-influenza agents.
Chen CL; Lin TC; Wang SY; Shie JJ; Tsai KC; Cheng YS; Jan JT; Lin CJ; Fang JM; Wong CH
Eur J Med Chem; 2014 Jun; 81():106-18. PubMed ID: 24836064
[TBL] [Abstract][Full Text] [Related]
5. Novel N-Substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies.
Ye J; Yang X; Xu M; Chan PK; Ma C
Eur J Med Chem; 2019 Nov; 182():111635. PubMed ID: 31493744
[TBL] [Abstract][Full Text] [Related]
6. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Yamashita M; Tomozawa T; Kakuta M; Tokumitsu A; Nasu H; Kubo S
Antimicrob Agents Chemother; 2009 Jan; 53(1):186-92. PubMed ID: 18955520
[TBL] [Abstract][Full Text] [Related]
7. Oseltamivir hydroxamate and acyl sulfonamide derivatives as influenza neuraminidase inhibitors.
Hong BT; Chen CL; Fang JM; Tsai KC; Wang SY; Huang WI; Cheng YE; Wong CH
Bioorg Med Chem; 2014 Dec; 22(23):6647-6654. PubMed ID: 25456388
[TBL] [Abstract][Full Text] [Related]
8. Divalent oseltamivir analogues as potent influenza neuraminidase inhibitors.
Yan ZL; Liu AY; Wei XX; Zhang Z; Qin L; Yu Q; Yu P; Lu K; Yang Y
Carbohydr Res; 2019 May; 477():32-38. PubMed ID: 30954773
[TBL] [Abstract][Full Text] [Related]
9. A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir.
Somasundaram B; Fee CJ; Fredericks R; Watson AJ; Fairbanks AJ; Hall RJ
J Mol Recognit; 2015 Sep; 28(9):521-7. PubMed ID: 25727669
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
11. Neuraminidase inhibitor resistance in influenza viruses.
Reece PA
J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
[TBL] [Abstract][Full Text] [Related]
13. Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Koch O; Seidel N; Schmidtke M; Clement B
J Med Chem; 2014 Feb; 57(3):759-69. PubMed ID: 24422530
[TBL] [Abstract][Full Text] [Related]
14. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
Neri-Bazán RM; García-Machorro J; Méndez-Luna D; Tolentino-López LE; Martínez-Ramos F; Padilla-Martínez II; Aguilar-Faisal L; Soriano-Ursúa MA; Trujillo-Ferrara JG; Fragoso-Vázquez MJ; Barrón BL; Correa-Basurto J
Eur J Med Chem; 2017 Mar; 128():154-167. PubMed ID: 28182988
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo.
Chand P; Bantia S; Kotian PL; El-Kattan Y; Lin TH; Babu YS
Bioorg Med Chem; 2005 Jun; 13(12):4071-7. PubMed ID: 15911320
[TBL] [Abstract][Full Text] [Related]
16. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Yamashita M
Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
18. Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidases as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay.
Quosdorf S; Schuetz A; Kolodziej H
Molecules; 2017 Nov; 22(11):. PubMed ID: 29149072
[TBL] [Abstract][Full Text] [Related]
19. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
Wang D; Sleeman K; Huang W; Nguyen HT; Levine M; Cheng Y; Li X; Tan M; Xing X; Xu X; Klimov AI; Gubareva LV; Shu Y
Antiviral Res; 2013 Mar; 97(3):240-4. PubMed ID: 23267831
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
